This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herling, A. W. Articles by Kramer, W. Search for Related Content PubMed PubMed Citation Articles by Herling, A. W. Articles by Kramer, W.

Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats

Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt/Main, Germany

Address all correspondence and requests for reprints to: Dr. Andreas W. Herling, Therapeutic Department Metabolism, Pharmacology, H 821, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt/Main, Germany. E-mail: andreas.herling{at}sanofi-aventis.com.

The CB1 receptor antagonist, rimonabant, affects the endocannabinoid system and causes a sustained reduction in body weight (BW) despite the transient nature of the reduction in food intake. Therefore, in a multiple-dose study, female candy-fed Wistar rats were treated with rimonabant (10 mg/kg) and matched with pair-fed rats to distinguish between hypophagic action and hypothesized effects on energy expenditure. Within the first week of treatment, rimonabant reduced BW nearly to levels of standard rat chow-fed rats. Evaluation of energy balance (energy expenditure measured by indirect calorimetry in relation to metabolizable energy intake calculated by bomb calorimetry) revealed that increased energy expenditure based on increased fat oxidation contributed more to sustained BW reduction than reduced food intake. A mere food reduction through pair feeding did not result in comparable effects because animals reduced their energy expenditure to save energy stores. Because fat oxidation measured by indirect calorimetry increased immediately after dosing in the postprandial state, the acute effect of rimonabant on lipolysis was investigated in postprandial male rats. Rimonabant elevated free fatty acids postprandially, demonstrating an inherent pharmacological activity of rimonabant to induce lipolysis and not secondarily postabsorptively due to reduced food intake. We conclude that the weight-reducing effect of rimonabant was due to continuously elevated energy expenditure based on increased fat oxidation driven by lipolysis from fat tissue as long as fat stores were elevated. When the amount of endogenous fat stores declined, rimonabant-induced increased energy expenditure was maintained by a re-increase in food intake.

This article has been cited by other articles:

				M. Flamment, N. Gueguen, C. Wetterwald, G. Simard, Y. Malthiery, and P.-H. Ducluzeau Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E1162 - E1170. [Abstract] [Full Text] [PDF]

				J. M. Richey, O. O. Woolcott, D. Stefanovski, L. N. Harrison, D. Zheng, M. Lottati, I. R. Hsu, S. P. Kim, M. Kabir, K. J. Catalano, et al. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1311 - E1318. [Abstract] [Full Text] [PDF]

				S. Migrenne, A. Lacombe, A.-L. Lefevre, M.-P. Pruniaux, E. Guillot, A.-M. Galzin, and C. Magnan Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R929 - R935. [Abstract] [Full Text] [PDF]